The effect of pravastatin on renal function and lipid metabolism in patients with renal dysfunction with hypertension and hyperlipidemia

Clinical and Experimental Hypertension

Volumn 21, Issue 8, 1999, Pages 1345-1355

  Imai, Yutaka ^b   Suzuki, Hiromichi ^a   Saito, Takao ^c   Tsuji, Ichiro ^b   Abe, Keishi ^c   Saruta, Takao ^a  

^a KEIO UNIVERSITY   (Japan)

^b TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NONE

Author keywords

Calcium entry blocker; Hyperlipidemia; Hypertension; Pravastatin; Renal dysfunction

Indexed keywords

AMLODIPINE; BENIDIPINE; CHOLESTEROL; DIHYDROPYRIDINE DERIVATIVE; MANIDIPINE; MEPIRODIPINE; NICARDIPINE; NIFEDIPINE; NILVADIPINE; NISOLDIPINE; PRAVASTATIN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; LIPID METABOLISM; MAJOR CLINICAL STUDY; SYSTOLIC BLOOD PRESSURE; UREA NITROGEN BLOOD LEVEL;

EID: 0032733270     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969909070853     Document Type: Article

References (28)

1. Neaton JD, Wentworth D: Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Arch Intern Med 152:56-64, 1992
2. Rosansky S, Hoover D, King L, Gibson J: The association of blood pressure levels and change in renal function in hypertensive and non-hypertensive subjects. Arch Intern Med 150: 2073-2076, 1990
3. Walser M : Progression of chronic renal failure in man. Kidney Int 37:1195-1210, 1990
4. Attman P, Alaupovic P: Lipid abnormalities in chronic renal insufficiency. Kidney Int 39 (Suppl 31): S16-S23, 1991
5. Guijarro C, Keane WF: Lipid abnormalities and changes in plasma proteins in glomerular diseases and chronic renal failure. Curr Opin Nephrol Hypertens 2:372-379, 1993
6. Moorhead JF: Lipids and the pathogenesis of kidney disease. Am J Kidney Dis 17 (Suppl 1):65-71, 1991
7. Guijarro C, Keane WF: Lipid induced glomerular injury. Nephron 67:1-6, 1994
8. Kasiske BL, Umen AJ: Persistent hyperlipidemia in renal transplant patients. Medicine 66:309-316, 1987
9. Samuelsson D, Mulec H, Knight-Gibson C, Attman PO, Kron B, Larsson R, Weiss L, Wedel H, Alauporic P: Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 12:1908-1915, 1997
10. Tolins JP, Stone BG, Raiji L: Interactions of hypercholesterolemia and hypertension in initiation of glomerular injury. Kidney Int 41:1254-1261, 1992
11. Kasiske BL, O'Donnell MP, Keane WF: Zuker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19:I-110-I-115, 1992
12. Hirano T, Morohoshi T: Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis. Nephron 60:443-447, 1992
13. Kasiske BL, O'Donnell MP, Garvis WJ, Keane WF: Pharmacologic treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 62:367-374, 1988
14. Harris KPG, Purkerson ML, Yates J, Klahr S: Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kid Dis 15: 16-23, 1990
15. Moorhead JF, Chan MK, EI-Nahas M, Varghese Z: Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet ii:1309-1311, 1982
16. Sasaki T, Kurata H, Nomura K, Utsunomiya K, Ikeda Y: Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus. Jpn J Med 29:156-163, 1990
17. Ravelink AJ, Hene RJ, Erkelens DW, Joles JA, Koomans HA: Partial remission of nephrotic syndrome in patients on long-term simvastatin. Lancet 335:1045, 1990
18. Byington RP, Jukema JW, Salonen JT, Pitt B, Bruschke AV, Hoen H, Furberg CD, Mancini J: Reduction in cardiovascular events during pravastatin therapy. Pooled analysis of clinical events of the pravastatin atherosclerosis intervention program. Circulation 92:2419-2425, 1995
19. Jukema JW, Bruschke AVG, van Boven A, Reiber JHC, Bal ET, Zwinderman AH, Jansen H, Boerma GJM, van Rappard FM, Lie KI: Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. The Regression Growth Evaluation Statin Study (REGRESS). Circulation 91:2528-2540, 1995
20. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Eng J Med 333:1301-1307, 1995
21. Kasiske BL, Velosa JA, Halstenson CE, Belle PL, Langendorfer A, Keane WF: The effects of lovastatin in hyperlipidemic patients with the nephrotic syndrome. Am J Kidney Dis 15:8-15, 1990
22. Golper TA, Illingworth DR, Morris CD, Benett WM: Lovastatin in the treatment of multifactorial hyperlipidemia associated proteinuria. Am J Kidney Dis 13:312-320, 1989
23. Chan PC, Robinson JD, Yeung WC, Cheng IKP, Yeung WHD, Tsand MTS: Lovastatin in glomerulonephritis patients with hyperlipidaemia and heavy proteinuria. Nephrol Dial Transplant 7:93, 1992
24. Grandaliano G, Biswas P, Choudhury GG, Abboud HE: Simvastatin inhibits PDGF-induced DNA synthesis in human glomerular mesangial cells. Kidney Int 44:503-508, 1993
25. O'Donell MP, Kasiske BL, Kim Y, Atluru D, Keane WF: Lovastatin inhibits proliferation of rat mesangial cells. J Clin Invest 91:83-87, 1993
26. Park Y-S, Guijarro C, Kim Y, Massy ZA, Kasiske BI, Keane WF, O'Donell MP: Lovastatin reduces glomerular macrophages influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 31:190-164, 1998
27. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 343:425-430, 1990
28. Guijarro C, Keane WF: Effects of lipids on the pathogenesis of progressive renal failure. Miner Electrolyte Metab 22:147-152, 1996